PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kidney transplant patients facing advanced skin cancer
Disease control OngoingThis early-stage study tests a combination of drugs (tacrolimus, nivolumab, and ipilimumab) in 12 kidney transplant recipients who have advanced skin cancers that cannot be surgically removed. The goal is to see if this treatment can shrink or control the cancer while keeping the…
Matched conditions: PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Immunotherapy after surgery shows promise against rare skin cancer
Disease control OngoingThis study tests whether the immunotherapy drug pembrolizumab can keep Merkel cell cancer from returning after it has been surgically removed. About 280 adults with stage I–III Merkel cell cancer will either receive pembrolizumab or be observed (standard care). The goal is to see…
Matched conditions: PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC